Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Soligenix Inc. (SNGX : NSDQ)

• Company Description    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $0.72 Daily Weekly Monthly 20 Day Moving Average: 860,877 shares Shares Outstanding: 2.98 (millions) Market Capitalization: $2.14 (millions) Beta: 1.76 52 Week High: $14.98 52 Week Low: $0.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -68.42% -69.62% 12 Week -76.47% -78.16% Year To Date -89.38% -90.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 29 EMMONS DRIVE SUITE B-10 - PRINCETON,NJ 08540 USA ph: 609-538-8200 fax: 609-452-6467 ir@soligenix.com http://www.soligenix.com

• General Corporate Information    Officers Christopher J. Schaber - Chief Executive Officer; Chairman and President Jonathan Guarino - Chief Financial Officer; Senior Vice President and Gregg A. Lapointe - Director Diane L Parks - Director Robert J. Rubin - Director Peer Information Soligenix Inc. (CORR.) Soligenix Inc. (RSPI) Soligenix Inc. (CGXP) Soligenix Inc. (BGEN) Soligenix Inc. (GTBP) Soligenix Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 834223505 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/11/23 Share - Related Items Shares Outstanding: 2.98 Most Recent Split Date: 2.00 (0.07:1) Beta: 1.76 Market Capitalization: $2.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.04 EPS Growth vs. Year Ago Period: 75.99% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 36.70% vs. Previous Quarter: -29.74% ROE 03/31/23 - - 12/31/22 - -589.84 09/30/22 - -261.52 ROA 03/31/23 - -64.89 12/31/22 - -71.43 09/30/22 - -65.65 Current Ratio 03/31/23 - 0.94 12/31/22 - 0.84 09/30/22 - 1.81 Quick Ratio 03/31/23 - 0.94 12/31/22 - 0.84 09/30/22 - 1.81 Operating Margin 03/31/23 - -996.96 12/31/22 - -1,403.04 09/30/22 - -1,650.62 Net Margin 03/31/23 - -996.96 12/31/22 - -1,403.04 09/30/22 - -1,650.62 Pre-Tax Margin 03/31/23 - -1,218.01 12/31/22 - -1,575.66 09/30/22 - -1,780.96 Book Value 03/31/23 - -1.14 12/31/22 - -0.85 09/30/22 - 0.36 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - - 09/30/22 - 6.67 Debt-to-Capital 03/31/23 - - 12/31/22 - - 09/30/22 - 86.97

Powered by Zacks Investment Research ©